Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
This certificate course provides advanced content in an optimized learning experience to support safe administration and application of evidence to manage the side effects and adverse events associated with antineoplastic administration.
This module explores the considerations and principles of comprehensive survivorship care of patients with cancer. Learn considerations of each treatment modality, psychosocial and spiritual impacts of treatment, best practice, and the essential influence of the advanced practice provider in care of the cancer survivor.
This module, a part of the comprehensive Hematopoietic Stem Cell Transplantation course, provides an overview of graft-versus-host disease (GVHD), a common complication of stem cell transplant.
This comprehensive course will enhance your understanding of hematopoietic stem cell transplant (HSCT) and provide concepts to apply to your care of HSCT patients.
After clinical trial outcomes demonstrated a statistically significant difference in progression-free survival in a subgroup of patients with estrogen receptor-positive, HER2-negative, ESR1-altered disease, the U.S. Food and Drug Administration granted elacestrant’s (Orserdu™) application priority review and fast-track designation, with regular approval in January 2023.
Demonstrating a 61% overall response rate with 38% of patients achieving complete response, epcoritamab-bysp (Epkinly™) became the first CD20-bispecific antibody drug available for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when the U.S. Food and Drug Administration granted it accelerated approval in May 2023. A phase III trial is currently underway to confirm its clinical benefit compared to the current standard of care for relapsed or refractory DLBCL.
Intentional, facilitated conversations are opportunities for healthcare staff to gather outside of patient care, meetings with agendas, or formal conferences. The ability, time, and space to connect in a way that allows speaking with intention and listening with attention supports individual and team resilience.
When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration (FDA) approved it for use in 2019.